Analyst Reco. CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
1.64 ^USD	-1.80%		-3.53%	+5.81%

May. 28	Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25	MT
May. 09	BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25	May. 28	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating	May. 09	MT
Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3	May. 09	MT
Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8	May. 06	MT
JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight	Apr. 22	MT
BMO Capital Adjusts CytomX Therapeutics Price Target to $3.25 From $3.30, Maintains Market Perform Rating	Mar. 12	MT
Wedbush Lifts CytomX Therapeutics' PT to $3 From $2, Says Focused Pipeline Moving Forward; Keeps Neutral Rating	Nov. 09	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.19 From $3.15, Keeps Market Perform Rating	23-08-09	MT
Mizuho Securities Adjusts CytomX Therapeutics Price Target to $2 From $4, Maintains Neutral Rating	23-03-28	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.20 From $2.60, Maintains Market Perform Rating	23-01-06	MT
BMO Capital Downgrades CytomX Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2.60 From $3	22-11-14	MT
JPMorgan Downgrades CytomX Therapeutics to Underweight From Overweight	22-11-10	MT
Cowen Downgrades CytomX Therapeutics to Market Perform From Outperform	22-07-11	MT
HC Wainwright Downgrades CytomX Therapeutics to Neutral From Buy	22-07-11	MT
Jefferies Downgrades CytomX Therapeutics to Hold From Buy, Lowers Price Target to $2 From $12	22-07-07	MT
Piper Sandler Downgrades CytomX Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.50 From $10	22-07-07	MT
BTIG Lowers CytomX Therapeutics' Price Target to $8 From $16, Buy Rating Kept	22-07-07	MT
BMO Capital Lowers CytomX Therapeutics' Price Target to $3 From $9, Outperform Rating Maintained	22-07-07	MT
Barclays Adjusts CytomX Therapeutics' Price Target to $3.50 From $7, Keeps Overweight Rating	22-07-07	MT
Wedbush Cuts CytomX Therapeutics to Neutral From Outperform, Price Target to $2 From $6, Citing Praluzatamab Ravtansine Update, 'Tough Financing Environment'	22-07-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Analyst Reco.

Filters